In our study cases, TGF-β1/ TGF-β1 receptor expressions with a higher Smad3/Smad2 ratio was observed in Subtype II adenomyosis cases, while Subtype I cases showed no significant modification of TGF-β1signaling proteins. This evidence concerns the gene SMAD3 and adenomyosis.